| (Values in U.S. Thousands) | Mar, 2026 | Mar, 2025 | Mar, 2024 | Mar, 2023 | Mar, 2022 |
| Sales | 148,870 | 84,040 | 56,630 | 34,160 | 32,260 |
| Sales Growth | +77.14% | +48.40% | +65.78% | +5.89% | +27.11% |
| Net Income | 44,870 | -4,310 | 20,110 | 3,560 | 8,900 |
| Net Income Growth | +1,141.07% | -121.43% | +464.89% | -60.00% | +74.85% |
Elite Pharms Inc (ELTP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Elite Pharmaceuticals, Inc. primarily engages in researching, developing, licensing, manufacturing, and marketing proprietary drug delivery systems and products. Their drug delivery technology involves releasing a drug into the bloodstream or delivering it to a target site in the body over an extended period of time or at predetermined times.
Fiscal Year End Date: 03/31